VEGFA and hepatocellular carcinoma: In the SHARP trial, Llovet and co-workers found that low VEGF-A and Ang-2 plasma baseline concentrations predicted survival in patients with advanced HCC and that high baseline plasma Ang-2 levels were related with a more aggressive disease [5].